Bis(maltolato)oxovanadium(IV)

CAS No. 38213-69-3

Bis(maltolato)oxovanadium(IV)( BMOV | Bis(maltolato)oxovanadium (IV) )

Catalog No. M27534 CAS No. 38213-69-3

BMOV is a potent, reversible, competitive and orally active pan-PTP (protein tyrosine phosphatases)inhibitor with insulin-mimicking effects and anti-diabetic properties.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 41 In Stock
5MG 37 In Stock
10MG 56 In Stock
25MG 116 In Stock
50MG 183 In Stock
100MG 291 In Stock
200MG 435 In Stock
500MG 700 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Bis(maltolato)oxovanadium(IV)
  • Note
    Research use only, not for human use.
  • Brief Description
    BMOV is a potent, reversible, competitive and orally active pan-PTP (protein tyrosine phosphatases)inhibitor with insulin-mimicking effects and anti-diabetic properties.
  • Description
    BMOV is a potent, reversible, competitive and orally active pan-PTP (protein tyrosine phosphatases)inhibitor with insulin-mimicking effects and anti-diabetic properties. BMOV is a potent insulin sensitize. BMOV is shown to improve cardiac dysfunctions in diabetic models. BMOV inhibits HCPTPA, PTP1B, HPTPβ and SHP2 with IC50s of 126 nM, 109 nM, 26 nM and 201 nM, respectivelyr.(In Vitro):BMOV treatment enhances the phosphorylation of the insulin receptor and of the insulin signalling key intermediate Akt. BMOV treatment also resultes in an increased glucose uptake in C2C12 cells.(In Vivo):BMOV (0.75-3.0 mmol; intraperitoneal injection; twice weekly; for 6 weeks; Male C57BL/6J mice) treatment ameliorates the metabolic phenotype, as evidenced by reduced body weight, improved insulin sensitivity and glucose tolerance.
  • In Vitro
    Bis(maltolato)oxovanadium(IV) treatment enhances the phosphorylation of the insulin receptor and of the insulin signalling key intermediate Akt. Bis(maltolato)oxovanadium(IV) (BMOV; 50 μM) treatment also resultes in an increased glucose uptake in C2C12 cells.
  • In Vivo
    Bis(maltolato)oxovanadium(IV) (BMOV; 0.75-3.0 mmol; intraperitoneal injection; twice weekly; for 6 weeks; C57BL/6J mice) treatment ameliorates the metabolic phenotype. Liver, skeletal muscle, and adipose tissue revealed a significantly reduced PTP activity in all analysed tissues compared to HFD mice. Animal Model:C57BL/6J mice (4-6 weeks) fed with high-fat diet (HFD) Dosage:0.75-3.0 mmol Administration:Intraperitoneal injection; twice weekly; for 6 weeks Result:Ameliorated the metabolic phenotype, as evidenced by reduced body weight, improved insulin sensitivity and glucose tolerance.
  • Synonyms
    BMOV | Bis(maltolato)oxovanadium (IV)
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    Phosphatase
  • Recptor
    Apoptosis
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    38213-69-3
  • Formula Weight
    317.15
  • Molecular Formula
    C12H10O7V
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 25 mg/mL (78.83 mM)
  • SMILES
    CC(OC=C1)=C([O-]2)C1=O[V+2]23(O=C4C=COC(C)=C4[O-]3)=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Ha TJ, Kubo I. Lipoxygenase inhibitory activity of anacardic acids. J Agric Food Chem. 2005 Jun 1;53(11):4350-4.
molnova catalog
related products
  • MP07-66

    MP07-66 is a novel FTY720-analog devoid of immunosuppressive effects leads to the reactivation of PP2A, which in turn triggers apoptosis of CLL cells.

  • Desfesoterodine

    5-hydroxymethyl tolterodine (PNU 200577) is a new muscarinic receptor antagonist with Kb of 0.84 nM.

  • EWP 815

    EWP 815 is a disulfiram analogue that functions as a powerful inhibitor of Ins(1,4) P 2 phosphatase, Ins(1,4,5) P 3 5-phosphatase, and dopamine β-hydroxylase activity .